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Summary 
Taxol is the prototype of a new dass of microtubule stabilizing agents with promising anticancer 
activity. Several studies show that taxol mimics the actions of lipopolysaccharide (LPS) on murine 
macrophages. To investigate the mechanism of taxol-induced macrophage stimulation, we evaluated 
the ability of Rhodobacter sphaeroides diphosphoryl lipid A (RsDPLA) and SDZ 880.431 to block 
taxol-induced effects. RsDPLA and SDZ 880.431 are lipid A analogues that lack LPS-like activity, 
but inhibit the actions of LPS, presumably by blocking critical cellular binding sites. We report 
that RsDPLA and SDZ 880.431 potently inhibited taxol-induced TNF secretion, gene activation, 
and protein-tyrosine phosphorylation. The role of microtubules in taxol signaling was investigated. 
Taxol-induced microtubuh bundling in primary and transformed RAW 264.7 macrophages was 
not blocked by RsDPLA or SDZ 880.431.  Taxotere, a semisynthetic taxoid, was more potent 
than taxol as an inducer of microtubule bundling, but did not induce tumor necrosis factor o~ 
secretion and gene activation. These data dissociate the microtubule effects of taxol from macrophage 
stimulation and suggest that taxol stimulates macrophages through an LPS receptor-dependent 
mechanism. The results underscore the potential of taxol as a tool for studying LPS receptor 
activation and provide insights into possible  therapeutic actions of this new class of drugs. 
M 
ammalian host defense mechanisms have evolved to 
recognize trace amounts of Gram-negative bacterial 
outer membrane, namely, endotoxin, and to respond in an 
integrated fashion involving each major effector arm of the 
immune system (1). In extreme cases, autonomic systems in- 
volved in homeostasis are dysregulated, as occurs during septic 
shock (2). Despite the complexity and potential violence of 
this response, only recently has there been significant under- 
standing of how endotoxin interacts with cells at the molec- 
ular level (3, 4).  The major component of endotoxin, i.e., 
LPS, appears to exist in the extraceUular milieu as a complex 
with one or more plasma proteins. Select proteins increase 
the efficiency  of LPS binding to CD14, a phosphatidylinositol- 
anchored membrane protein expressed by macrophages and 
neutrophils (5-9). Delivery of LPS to CD14 is required (8, 
9), but not sufficient, for LPS stimulation of macrophages. 
This is illustrated by the finding that the inactive lipid A ana- 
logue, lipid IVA, suppresses LPS signaling under conditions 
that do not block LPS binding to CD14 (9). Consequently, 
it has been speculated that CD14 serves to facilitate delivery 
of LPS to an as yet unidentified LPS "receptor" protein (4). 
Identification of this putative receptor is an area of active in- 
vestigation. 
Taxol  1 is the first effective anticancer agent with a novel 
mechanism of action to be developed in over a decade, and 
it has generated considerable enthusiasm in the oncology com- 
munity due to its favorable response rate in patients with 
advanced metastatic ovarian, breast, and lung cancer (10). Taxol 
is a complex diterpenoid isolated from the bark of the Padfic 
yew (Fig. 1). The antiproliferative  effects of taxol appear to 
be related to its ability to bind/3-tubulin and stabilize microtu- 
bules (11-13). The dynamic depolymerization necessary for 
microtubule function during  mitosis  (and  other  cellular 
processes) is blocked. Taxol-treated cells develop large bundles 
of microtubules and multiple mitotic asters and are arrested 
in the M phase of the cell cycle (14). Numerous taxol ana- 
logues have been generated by semisynthetic approaches (13, 
15). One of these,  taxotere  2, is approximately twice as po- 
1 World Health Organization generic name is paditaxel. 
2 World Health Organization generic name is docetaxel. 
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tion assays (15) and is also being tested in clinical trials (16). 
Nature may have provided in taxol an invaluable tool for 
dissecting LPS-signaling pathways. Ding et al.  (17) discov- 
ered that  taxol exhibited profound cell cycle-independent 
effects on murine macrophages. Taxol activated the acute in- 
ternalization of TNF-ce receptors and initiated a slower in- 
duction of TNF-oL protein, properties that were remarkable, 
in part, because they were shared by LPS. Further investiga- 
tion revealed that this activity of taxol was restricted to mac- 
rophages from mice bearing the wild-type Lps  ~ gene, i.e., 
responsiveness  to taxol was genetically linked to responsive- 
ness to LPS. Subsequently, taxol was shown to stimulate a 
panel of macrophage responses in a manner virtually iden- 
tical to LPS (18-20).  Taxol activated the expression of six 
of six LPS-inducible genes with kinetics and amplitude in- 
distinguishable from LPS, and taxol, like LPS, induced rap- 
idly the tyrosine phosphorylation of several 41-45-kD pro- 
teins (18, 20). In toto, the overlapping activities of taxol and 
LPS suggest the two agents share signaling pathways. Re- 
cently, Ding et al. (21) have presented the provocative finding 
that LPS binds specifically and with high aff~ty to B-tubulin, 
providing a potential mechanism by which taxol and LPS 
could induce shared responses. 
A second set of tools useful in studying LPS signaling in- 
dude several synthetic/natural lipid A and lipid X analogues 
that lack LPS-like activity, but that retain the ability to block 
LPS stimulation of various cell types. It is believed that they 
represent competitive inhibitors of LPS binding to its critical 
receptor(s) due to their structural similarity to the active center 
of LPS, namely, lipid A, and because they are highly specific 
inhibitors of LPS (i.e., they do not block other macrophage 
activating agents such as Gram-positive cell wails, phorbol 
ester,  or cytokines [9,  22,  22a]),  and can be overridden in 
the presence of excess LPS (9, 22-25). Rhodobacter sphaeroides 
diphosphoryl lipid A (RsDPLA) 3 is one of the best charac- 
terized  LPS  "antagonists"  (Fig.  1).  Initially  purified  by 
Takayama et al.  (26) and chemically defined by Qureshi et 
al. (27), RsDPLA has been used to block LPS-induced TNF 
production in vivo (28) and by monocytes/macrophages in 
vitro (22,  26,  28,  29). Others have reported that RsDPLA 
blocks LPS-induced pre-B cell activation (23) and CD18 sur- 
face expression on human neutrophils (24).  In addition to 
other lipid A analogues, several synthetic monosaccharide de- 
rivatives also have inhibitory activity (25, 30). SDZ 880.431 
(3-aza-lipid  X 4-phosphate) (Fig.  1) has been well character- 
ized and shown to inhibit LPS-induced macrophage TNF 
secretion (31), neutrophil CD18 expression (25), and expres- 
sion of procoagulant activity in cultures of human PBMC 
(30). In general, disaccharide inhibitors are approximately an 
order of magnitude more potent than monosaccharide in- 
hibitors. 
In the present study, we investigated further the relation- 
ship between taxol- and LPS-sigualing pathways. We have 
3 Abbreviation used in this paper: RsDPLA, Rhodobacter  sphaeroides diphos- 
phoryl lipid A. 
used RsDPLA and SDZ 880.431 as tools to suggest that taxol 
stimulates routine macrophages through an LPS receptor-de- 
pendent pathway, and to dissociate taxol-induced signaling 
from taxol-induced microtubule changes. 
Materials and Methods 
Reagents.  Protein-free  (<0.008%), phenol/water-extracted  Esch- 
erichia coli K235 LPS was prepared by the method of Mclntire et 
al. (32). RsDPLA was prepared as described previously (27). SDZ 
880.431 was synthesized  by Sandoz Research  Institute (3/ienna, Aus- 
tria) as described (30). Taxotere was a kind gift of RhOne-Poulenc 
Rorer (Vitry Sur Seine, France). Taxol was provided by the Drug 
Synthesis and Chemistry Branch, Developmental  Therapeutics Pro- 
gram, Division of Cancer Treatment, National Cancer Institute 
(Bethesda, MD), and was stored at - 70~  as a 10-mM stock solu- 
tion in DMSO. The highest concentration of DMSO (0.3%) used 
in these studies did not induce LPS-indudble  genes or tyrosine phos- 
phorylation. A l-raM dilution of taxol contained <0.03 EU/ml 
by Limulus amoebocyte  lysate  assay,  corresponding to approximately 
<90 fg/ml LPS in a 30-/~M taxol solution; minimum concentra- 
tions of LPS required to induce gene expression and tyrosine phos- 
phorylation were 0.1 and 1 ng/ml, respectively. 
Primary Macrophage Isol,,tion and Culture  Thioglycollate-elicited 
peritoneal macrophages from C3H/OuJ mice (The Jackson Labo- 
ratory, Bar Harbor,  ME) were isohted and cultured  (2  x  106 
cells/ml) in complete medium (RPMI 1640 supplemented with 2 
mM glutamine, 100 U/ml penicillin, 100/~g/ml streptomycin, 10 
mM Hepes, 0.3%  sodium bicarbonate, and 2% heat-inactivated 
FCS) as described previously (18). Cells were cultured at 37~  and 
6% CO2, and nonadherent cells were removed by washing with 
media 2-4 h after phting. For TNF secretion studies, 2  x  10  s 
cells/well were plated into Falcon 96-well microtiter phtes (Becton 
Dickinson & Co., Lincoln Park, NJ). For Northern blot analysis, 
4  x  106 cells/well were cultured in six-well  polystyrene tissue cul- 
ture plates (Becton Dickinson  & Co.).  For analysis of protein- 
tyrosine phosphorylation,  106 cells/well were plated into 24-well 
culture plates (Costar Corp.,  Cambridge, MA). 
TNF-~ Bioassay.  4-h culture  supernatants were assayed for 
TNF-~  bioactivity  in  a  cytotoxicity  assay using  actinomycin 
D-treated L929 cells as described previously (18). 
Northern Blot Analysis of Taxoi-induced Genes.  Adherent macro- 
phages were cultured for 4 h with the indicated stimuli, lysed in 
1 ml of RNAzol B (Tel-Test, Inc., Friendswood, TX), and total 
RNA was isolated according to the manufacturer's instructions. 
RNA (5-10/~g) was fractionated on 1% agarose gels containing 
formaldehyde, transferred via capillary action to a Nytran filter 
(Schleicher & Schuell, Inc., Keene, NH), UV crosslinked to the 
filters, and hybridized overnight with random-primed ~-labeled 
eDNA probes, probes specific  for the transcripts encoding murine 
TNF-r*, TNFR-2, IL-lO, IP-10, D3, DS, and ~-actin were used 
in this study and have  been described  in detail previously  (18, 33-35). 
Hybridized blots were washed three times for 10 rain at 65~  in 
0.1x  SSC containing 0.1% SDS, and exposed to Kodak XAR-5 
film with intensifier screens for 18-24 h at 70~  The ratio of the 
signal between the probe of  interest and O-actin was used as a mea- 
sure of relative  induction. Between successive  hybridizations,  Nytran 
filters were boiled in distilled water for 5 min. 
An@hosphotyrosine Imraunoblotting.  Macrophages were cultured 
with treatments as indicated. At the end of the culture period, 
the media was rapidly rephced with 100 #l/well ice-cold  lysis  buffer 
(100 mM TrisHC1, pH 8.0; 100 mM NaC1; 2 mM EDTA; 1% NP- 
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citin;  1 mM PMSF; 1 #g/m1 leupeptin,  and pepstatin).  Culture 
plates were agitated in an ice water bath for 10 min, and cell lysates 
were transferred to microfuge tubes and centrifuged  (12,000 g for 
1 rain) to remove detergent-insoluble  material.  Supematants  (80 
#1) were boiled for 5 min with 28 #1 of 4 x  loading buffer (200 
mM Tris-HC1, pH 6.8,  10% SDS, 400 mM dithiothreitol,  40% 
glycerol, and 0.4% bromophenol blue), and 13 #l/lane was resolved 
by SDS-PAGE on 10% acrylamide gels (7 x 8 cm). The separating 
gel was buffered with 375 mM TrisHC1, pH 8.5. Resolved pro- 
teins were blotted onto Immobilon-P  transfer membranes (MiUi- 
pore Corp., Bedford, MA). Blots were blocked 1 h in wash buffer 
(20 mM Tris-HCl, pH 7.6, 137 mM NaCI,  and 0.1% Tween 20) 
containing  3% gelatin and 5% milk. Blots were then incubated 
I h in wash buffer containing  1 #g/ml antiphosphotyrosine  mAb 
(clone  4G10; Upstate  Biotechnology,  Inc.,  Lake Placid, NY), 
washed, and incubated with horseradish peroxidase-conjugated goat 
anti-mouse IgG (1:3,000 dilution;  Bin-Red Laboratories, Rich- 
mond, CA). Binding of secondary antibody was detected with the 
enhanced chemiluminescence (ECL) detection method (Amersham, 
Amersham, UK). Molecular weights of phosphoproteins were de- 
termined by comparison with prestained markers (Bio-Rad Labora- 
tories). 
lmmunofluorescent Detection of Microtubules.  RAW 264.7 cells 
(American Type Culture Collection,  RockviUe, MD) (maintained 
in DMEM containing 5% FCS) or primary macrophages were plated 
(2  x  10  s cells/well) onto Lab-Tek eight-well glass chamber slides 
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Figure  1.  Chemical  structures of taxol, RsDPLA, and SDZ 880.431. 
(Nunc,  Inc., Naperville, IL). RAW 264.7 cells were allowed to 
adhere and proliferate overnight. Cells were then pretreated 10 min 
with media alone or containing  2 #g/ml RsDPLA or 20 #g/ml 
SDZ 880.431. Where indicated, culture media was adjusted to con- 
tain 3 #M taxol, and the cells were cultured an additional 4 h be- 
fore fixation for 30 min at room temperature in 10% buffered for- 
malin.  Microtubules  were  visualized  in  fixed  cells  by 
immunofluorescence  as described previously (18) using  a rabbit 
anti-sea urchin tubulin IgG fraction (Polysciences,  Inc., Warrington, 
PA) and a fluoresceinated F(ab')2 fragment of goat anti-rabbit  IgG 
(Cappel Laboratories, Malvern, PA). 
Results 
Taxol-induced TNF Secretion Is Blocked by Lipid A-based LPS 
Inhibitors.  As a first approach to define the signaling mech- 
anism of taxol, the ability of RsDPLA to inhibit taxol-induced 
TNF secretion was evaluated. C3H/OuJ macrophages were 
treated with medium alone or with medium containing 30 
#M  taxol  with  or  without  increasing  concentrations  of 
RsDPLA. 4-h supernatants  were harvested and assayed for 
TNF activity (Fig. 2 A). RsDPLA (10-1,000 ng/ml) potently 
inhibited taxol-induced TNF secretion. We next determined 
if the  ability  of RsDPLA  to  block  taxol  was  specific  to 
RsDPLA or general to LPS antagonists.  SDZ 880.431 was 
selected  for  testing  due  to  its  structural  dissimilarity  to 
RsDPLA.  SDZ 880.431 effectively inhibited  taxol-induced 
TNF over a concentration range of 0.3-10 #g/ml (Fig. 2 B). 
The concentrations of RsDPLA and SDZ 880.431 found to 
inhibit taxol-induced TNF were virtually identical to the con- 
centrations required to block LPS (1 ng/ml)-induced macro- 
phage TNF secretion and gene expression (22a).  Although 
the taxol solutions contained no detectable activity in  the 
Limulus amoebocyte lysate assay (see Materials and Methods), 
the ability of polymyxin B to block taxol-induced TNF was 
tested to control for the presence of endotoxin (Fig.  2 C). 
Polymyxin B inhibited the TNF-inducing activity of 1 ng/ml 
LPS, but had no effect on a submaximal  concentration  of 
taxol (16 #M). 
Taxol-induced Gene Expression and TFosine Phosphorflation 
Is Blocked by Lipid A-based LPS Inhibitors.  Taxol induces the 
expression of TNF-ot and at least five other LPS-inducible 
genes (18). We next sought to determine ifRsDPLA blocks 
taxol-induced TNF-ot at the level ofmKNA induction, and, 
if so, whether blockade of taxol-induced responses is selec- 
tive or extends to the other inducible genes.  Fig.  3  shows 
that RsDPLA inhibited taxol-induced expression of TNF-cr 
and IL-1/3 mKNAs. In addition, RsDPLA inhibited the taxol- 
induced expression of transcripts encoding IP-10, TNFK-2, 
D3, and D8, and taxol-induced expression of this entire panel 
of genes was similarly blocked by 0.3-10/zg/ml SDZ 880.431 
(data not shown). Inhibition of gene expression by RsDPLA 
appeared to be of a competitive nature since it could be over- 
ridden by increasing  the concentration  of taxol (Fig.  4). 
One of the earliest biochemical events measurable during 
taxol and LPS signaling is tyrosine phosphorylation of 41.5-, 
43-, and 47-kD proteins (Fig. 5, solid lines between the two 
panels). This is accompanied by the apparent dephosphory- 
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LPS inhibitors block taxol-induced TNF secretion in murine  Figure  2. 
macrophages.  C3H/OuJ macrophages  were cultured 4 h in the presence 
of the indicated  stimuli and inhibitors,  and supernatants  were harvested 
and tested for TNF activity as described in Materials and Methods. RsDPLA 
and SDZ 880.431 were added to taxol solutions  simultaneously  with cell 
stimulation.  Polymyxin B was added to LPS and taxol solutions  15 min 
before cell stimulation.  (A) RsDPLA concentration-dependent inhibition 
of taxol  (30/~M)-induced  TNF secretion.  (B) SDZ 880.431 concentra- 
tion-dependent inhibition of taxol (30/xM)-induced  TNF secretion.  (C) 
Polymyxin B concentration-dependent effects on TNF secretion induced 
by I ng/ml LPS or 16 #M taxol. Values in A and B are mean values and 
SEM of three separate experiments. Values  in C are from a single experiment. 
Figure  3.  LPS inhibitors  block taxol-induced  gene expression in mu- 
fine macrophages. C3H/OuJ macrophages were cultured 4 h with 30 #M 
taxol with and without increasing concentrations  of RsDPLA. Cellular 
RNA was harvested and subjected to Northern blot analysis of TNF-c~, 
IL-I~, and ~8-actin  gene expression as described in Materials and Methods. 
Results  are representative  of two separate experiments. 
lation of 40.5- and 45-kD proteins  (Fig. 5, dotted lines). As 
little  as  30  ng/ml  RsDPLA  or  1  /zg/ml  SDZ  880.431 
significantly blocked  taxol-induced  protein-tyrosine phos- 
phorylation/dephosphorylation. 
Taxol-induced  Microtubule Changes Are Not Blocked by Lipid 
A-based LPS Inhibitors.  Untreated macrophages exhibit  a 
classic microtubule network that can be visualized by fluores- 
cence microscopy; delicately stained microtubules radiate out 
from a brightly stained perinudear cytocenter. Taxol, by virtue 
of its ability to stabilize microtubules against depolymeriza- 
tion, favors the formation of large bundles of microtubules 
that lack a cytocenter orientation (11, 18). Taxol selectively 
binds  microtubules,  and  microtubules have high  affinity 
binding sites for LPS (21). Consequently,  we reasoned that 
lipid A-based inhibitors may block taxol-induced cell stimu- 
lation by competing for microtubule binding sites. If so, 
RsDPLA  and  SDZ  880.431 should  block  taxol-induced 
microtubule  bundling. However, even when primary macro- 
phages were treated with a minimal stimulatory concentra- 
tion of taxol (3/~M), excess RsDPLA (2/~g/ml) or SDZ 
880.431 (20 #g/m1) failed to suppress taxol-induced microtu- 
bule bundling (not shown). Because microtubule bundling 
is difficult to measure, we sought a more quantitative  ap- 
proach to evaluate further the effects of RsDPLA and SDZ 
880.431 on microtubule stabilization. The RAW 264.7 rou- 
tine macrophage cell line responds to taxol with normal in- 
duction of microtubule bundling, TNF secretion, gene ex- 
pression,  and  tyrosine phosphorylation  (C.  L.  Manthey, 
unpublished  results). Because RAW 264.7 cells proliferate, 
a small fraction of the population is undergoing mitosis at 
any point in time. This fraction, referred to as the "mitotic 
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Figure  4.  Raising the concentration of taxol overrides RsDPLA inhi- 
bition of TNF-~ mRNA. C3H/OuJ macrophages were cultured 4 h with 
media alone or containing 20 ng/ml RsDPLA and increasing concentra- 
tions  of taxol.  Cellular  R.NA was harvested  and subjected to Northern 
blot analysis of  TNF-ol and ~-actin gene expression. Relative gene expres- 
sion was determined  by Phosphorlmaging as described in Materials and 
Methods. 
index" can be determined by counting the percentage of cells 
that  contain  mitotic spindles.  By stabilizing  microtubules, 
taxol induces the formation  of multiple,  dysfunctional mi- 
totic asters and blocks progression through mitosis.  Conse- 
quently,  RAW 264.7 cells  that  contain mitotic spindles or 
asters accumulated sevenfold when cultured 4 h in the pres- 
ence of taxol. As shown in Table 1, excess RsDPLA or SDZ 
880.431 did not reduce the percentage of cells blocked in mi- 
tosis by taxol. These results confirm that RsDPLA or SDZ 
880.431  do not inhibit  taxol-mediated  microtubule  stabili- 
zation. 
Taxotere Stabilizes Microtubules but Fails to Induce TNF Secre- 
tion or Gene Activation.  Taxotere is a semisynthetic  taxoid 
that is two- to threefold more potent than taxol as a microtu- 
Table  1.  Taxol-induced Mitotic Arrest Is Not Blocked by 
LPS Inhibitors 
Taxol  (3  /xM)  Inhibitor  Mitotic index" 
-  -  2.2 
-  RsDPLA  (2  #g/ml)  2.2 
-  SDZ 880.431  (40/~g/ml)  1.9 
+  -  15.2 
+  RsDPLA (2 ~g/ml)  15.7 
+  SDZ 880.431  (40/~g/ml)  17.6 
RAW 264.7  macrophages  were pretreated  10 min with indicated  lipid 
A-based inhibitor and  an additional  4 h  with media  alone or adjusted 
to contain 3/~M taxol. Cells were stained for microtubules  as described 
in Materials  and  Methods. 
* Mitotic index was determined  as the percentage  of cells exhibiting mi- 
totic spindles or mitotic asters. At least 500 cells per group were examined. 
bule stabilizing agent (15). In our experiments, bundling and 
aster formation in RAW 264.7 cells was induced by as little 
as 0.075/~M taxotere,  while 0.3 #M taxol was required to 
achieve  a comparable effect. To investigate further  the rela- 
tionship between microtubule stabilization and cell signaling, 
the ability of taxotere to induce murine macrophages to se- 
crete TNF and express TNF-c~ mRNA was examined (Fig. 
6).  Taxotere  did  not  induce  detectable  TNF  secretion  or 
mRNA expression. 
Discussion 
Taxol-induced  TNF secretion,  gene activation, and protein- 
tyrosine phosphorylation  were blocked by 10-1,000 ng/ml 
RsDPLA or 0.3-10/~g/ml  SDZ 880.431.  These concentra- 
tions of RsDPLA and SDZ 880.431  inhibit  LPS responses 
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Figure  5.  LPS  inhibitors  block  taxol-in- 
duced protein-tyrosine  phosphorylation.  Mac- 
rophages were cultured 10 rain with the indi- 
cated  concentrations  of  RsDPLA  or  SDZ 
880.431 and the media were adjusted to con- 
tain 0 or 30/~M taxol or 100 ng/ml LPS. After 
an additional  12 min (LPS) or 20 min (Taxol), 
cells were lysed and prepared for antiphospho- 
tyrosine  Western  blotting  as  described  in 
Materials and Methods.  Results  are represen- 
tative  of three separate experiments. 1000000 
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Figure 6.  Taxotere does not induce TNF-c~ rnRNA or activity. (right) 
C3H/OuJ macrophages were cultured 4 h in the presence of the indicated 
concentrations  of the taxanes: taxol or taxotere.  Supernatants  were har- 
vested and tested for TNF activity as described in Materials and Methods. 
Values are means of two separate experiments. (kfi) C3H/OuJ macrophages 
were cultured 4 h in the presence of media alone or containing taxotere 
(100 #M) or taxol (30/~M).  Cellular RNA was harvested and subjected 
to Northern blot analysis of TNF-o~ and 3-actin gene expression as de- 
scribed in Materials and Methods. Relative gene expression was determined 
by Phosphorlmaging analysis. Values are means of two separate experiments. 
in a similar fashion, but have  been shown to be inactive against 
macrophage stimulation by heat-killed Staphylococcus aureus, 
PMA, or cytokines (9, 22a, 25). We interpret these data to 
mean that occupancy of putative LPS receptors by LPS an- 
tagonists block taxol-induced LPS-mimetic activity. In the 
simplest model, taxol and LPS share a common receptor. 
Taxol-mediated  LPS receptor activation need not necessarily 
involve LPS receptor occupancy  by taxol. Microtubules regulate 
receptor cycling (36), and direct and indirect associations exist 
between microtubules  and membrane structural proteins. 
Taxol, by virtue of its effects on microtubules,  might per- 
turb an unidentified molecular link with the LPS receptor 
leading  to its  activation.  In this  model, occupancy of the 
receptor by lipid A-based antagonists would preclude con- 
version of the receptor to an active state. However, taxotere 
was unable to activate an LPS-like signal in murine macro- 
phages, although it induced the same degree of mitotic ar- 
rest and microtubule bundling as did taxol. These data argue 
against a model involving activation of LPS receptors through 
a microtubule-dependent  pathway. Conversely,  LPS antagonist- 
mediated taxol inhibition need not necessarily involve taxol 
"receptor" occupancy  by LPS antagonists. We cannot presently 
exclude  the possibility that occupancy  of  putative LPS receptors 
by LPS antagonists may indirectly sequester or immobilize 
a critical effector molecule of taxol signaling. 
Proteins that bind LPS and have a known or suspected role 
in LPS signaling include serum proteins such as lipapolysac- 
charide binding protein (LBP) (5) and septin (6); cell surface 
membrane proteins such as CD14 (7-9) and 73-kD protein 
(37); and 3-tubulin (21), a microtubule protein. Serum is not 
required for murine macrophage stimulation by taxol, or for 
inhibition of taxol by LPS inhibitors  (C. L. Manthey, un- 
published observations). Consequently,  LBP and septin are 
not likely to be involved in taxol stimulation of macrophages. 
The role of CD14 and 73-kD  protein in taxol signaling is 
unknown and under investigation.  LPS binds polymerized 
tubulin (21), and this provocative data suggest microtubules 
may be important binding sites for LPS and taxol stimula- 
tion of macrophages. However, the microtubule effects of 
taxol occur independently of macrophage stimulation.  As 
shown herein, RsDPLA and SDZ 880.431 blocked taxol stim- 
ulation of normal C3H/OuJ macrophages, but had no effect 
on microtubule bundling, and, conversely, taxotere induced 
microtubule bundling but did not induce LPS-like signaling. 
Moreover, taxol induces normal microtubule bundling in mac- 
rophages from C3H/HeJ (Lps a) mice, but fails to stimulate 
these cells (17, 18). Thus, microtubule stabilization induced 
by taxol and taxotere is not sufficient for stimulation of mac- 
rophages. 
It is our view that taxol signals through an as yet unrecog- 
nized protein,  and identification of this molecule will pro- 
vide needed insights  into the nature of the LPS-signaling 
receptor. Early binding studies with radiolabeled taxol iden- 
tified polymerized tubulin as the primary cellular target of 
taxol (11). More recently, direct photoaffinity labeling has 
demonstrated selective binding of taxol to 3-tubulin (12). 
Progress is being made in the development of taxol deriva- 
tives with photoactivatable crosslinking moieties to map more 
efficiently the 3-tubulin binding site (13). It will be impor- 
tant to determine if crosslinking derivatives of taxol retain 
LPS-mimetic activity, and to apply these derivatives to the 
identification of novel proteins that may also bind LPS and 
lipid A-based LPS inhibitors. 
Taxol represents the first of a class of new anticancer drugs, 
and much may be learned regarding tumor biology and treat- 
ment as the pharmacology of these agents is more completely 
understood. The mechanism of action of this group of agents 
is felt to reside in their ability to stabilize microtubules  and 
prevent cell progression  through mitosis. Our results sug- 
gest taxol may also activate putative LPS receptors on mu- 
rine macrophages. For decades investigators have known that 
LPS can cure rodents of tumors (38, 39), but the use of LPS 
in humans is confounded by its unacceptable toxicity. An- 
titumor activity of LPS arises, in part, from the ability of 
LPS to induce TNF and other cytokines and to serve as a 
second signal in the activation of macrophage nitric oxide 
synthase and tumoricidal activity (39, 40). LPS substructures 
have been identified that are relatively nontoxic, but that re- 
tain the antitumor activity of LPS (39). Two such  compounds, 
monophosphoryl lipid A and SDZ MILL 953, activate mu- 
rine macrophages in an LPS-like fashion and are blocked by 
lipid A-based inhibitors (29, 31). We propose that taxol, by 
analogy to these nontoxic LPS mimetics, may activate host 
antitumor activity. However, induction of TNF may not be 
required for the therapeutic efficacy  of  other taxoids. Although 
taxotere did not induce TNF in murine macrophages, recent 
phase II clinical trials indicate that taxotere is a highly effec- 
tive drug against breast cancer and other solid tumors (16). 
More work is required to determine if taxol can act as a second 
signal for induction of tumoricidal activity and to determine 
the cell specificity of the LPS-mimetic actions of taxol, e.g., 
it will be important to determine if taxol stimulates cell types 
other than macrophages, and if taxol activates genes in human 
immune or neoplastic tissues. 
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